Prevalence of Glaucoma Among US Adults in 2022
- PMID: 39418040
- DOI: 10.1001/jamaophthalmol.2024.3884
Prevalence of Glaucoma Among US Adults in 2022
Abstract
Importance: Glaucoma is the leading cause of irreversible blindness worldwide and, in the US, disproportionately affects people from racial and ethnic minority groups. Glaucoma prevalence has not been estimated for the US in more than a decade, and state- and county-level estimates are not available.
Objective: To estimate glaucoma and vision-affecting glaucoma prevalence by demographic factors and US state and county for the Centers for Disease Control and Prevention's Vision and Eye Health Surveillance System (VEHSS).
Data sources: This meta-analysis used data from the National Health and Nutrition Examination Survey (2005-2008), Medicare fee-for-service claims (2019), IBM MarketScan commercial insurance claims (2016), population-based studies of eye disease (1985-2003), and 2022 population estimates from the US Census Bureau.
Study selection: PubMed was searched for population-based studies of glaucoma prevalence published between 1991 and 2016.
Data extraction and synthesis: Bayesian meta-regression methods were used to estimate the prevalence of glaucoma and vision-affecting glaucoma stratified by age, undifferentiated sex/gender (a measure that captures an unclear mix of aspects of sex and or gender), race and ethnicity, and US county and state.
Main outcomes and measures: Prevalence of any type of glaucoma (open or closed angle) among people 18 years or older and vision-affecting glaucoma, defined as glaucoma and a visual field abnormality.
Results: For 2022, an estimated 4.22 million people (95% uncertainty interval [UI], 3.46 million to 5.23 million) in the US were living with glaucoma, with a prevalence of 1.62% (UI, 1.33%-2.00%) among people 18 years or older and 2.56% (UI, 2.10%-3.16%) among people 40 years or older. An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older. Prevalence of glaucoma among people 18 years or older ranged from 1.11% (UI, 0.89%-1.40%) in Utah to 1.95% (UI, 1.57%-2.39%) in Mississippi. Black adults had a prevalence of 3.15% (UI, 2.32%-4.09%) compared with 1.42% (UI, 1.10%-1.85%) among White adults; adults in the Hispanic and all other racial and ethnic categories combined had a prevalence of 1.56% (UI, 1.13%-2.06%).
Conclusions and relevance: This meta-analysis found that an estimated 2.56% of people 40 years or older have glaucoma, slightly more than estimated by previous studies. Black individuals are disproportionately affected. Prevalence estimates at the state and county level can help guide public health planning.
Similar articles
-
Prevalence of Diabetic Retinopathy in the US in 2021.JAMA Ophthalmol. 2023 Aug 1;141(8):747-754. doi: 10.1001/jamaophthalmol.2023.2289. JAMA Ophthalmol. 2023. PMID: 37318810 Free PMC article.
-
Prevalence of Age-Related Macular Degeneration in the US in 2019.JAMA Ophthalmol. 2022 Dec 1;140(12):1202-1208. doi: 10.1001/jamaophthalmol.2022.4401. JAMA Ophthalmol. 2022. PMID: 36326752 Free PMC article.
-
Routine eye examinations for persons 20-64 years of age: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(15):1-81. Epub 2006 Jul 1. Ont Health Technol Assess Ser. 2006. PMID: 23074485 Free PMC article.
-
Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis.Lancet Glob Health. 2017 Sep;5(9):e888-e897. doi: 10.1016/S2214-109X(17)30293-0. Epub 2017 Aug 2. Lancet Glob Health. 2017. PMID: 28779882 Review.
-
Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.Ophthalmology. 2014 Nov;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013. Epub 2014 Jun 26. Ophthalmology. 2014. PMID: 24974815 Review.
LinkOut - more resources
Full Text Sources
